You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍造好 康希諾、啟明、醫渡及華領急升11%-16%
港股連跌五個交易日,恆指現報18,807,反覆續跌81點或0.4%,總成交額僅715億元。 醫藥股今天普遍逆市造好,華領醫藥-B(02552.HK)扭四連跌,股價由上市低位反彈高見1.76元(受制10天線1.78元),現報1.73元,急升16%。醫渡科技(02158.HK)回升16%報6.2元,股價突破20天、10天及50天線(5.44-5.77元)。康希諾生物(06185.HK)由上市低位反彈高見27.5元,現報26.7元,揚11%。啟明醫藥-B(02500.HK)由上市低位急彈12%報6.04元。 微創機械人-B(02252.HK)重越20天及10天線,最高見20.4元,現報19.74元,回升8.9%。 基石藥業-B(02616.HK)及諾誠健華-B(09969.HK)終止連日下跌,股價由上市低位分別反彈高見2.54元及7.05元,現報2.44元及6.96元,回升5.6%及7.9%。獲革蘭氏陰性藥全球獨家開發權及擬悉售Qpex權益的菌騰盛博藥-B(02137.HK)彈逾半成曾高見4.15元。康寧傑瑞製藥-B(09966.HK)回升2%曾高見7.4元。 藍籌中生製藥(01177.HK)及藍籌翰森(03692.HK)升逾2.5%及5%,後者報12.86元,升5.2%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account